Preliminary results show several plasma proteins are statistically significant biomarkers for endometriosis. The results will be presented at the Fertility Society of Australia and New Zealand Annual Conference (FSANZ 2022), being held 30 July – 2 August in Sydney, NSW.
The next phase of analysis will use the validated biomarkers to build a diagnostic model, as was performed for PromarkerD, the Company’s novel diagnostic test for diabetic kidney disease (DKD). This process of statistical modelling will determine the accuracy (sensitivity and specificity) of the new test and will take approximately one month. These results will also be presented at FSANZ 2022. The Company will then seek to confirm the clinical performance of the new test in an independent patient cohort.
To support this independent validation, Proteomics International also announces an additional collaboration with St John of God Health Care. The Company has signed a material transfer agreement to access approximately 250 clinical samples from the St John of God Subiaco Hospital Gynaecological Cancer Research Group that were obtained from patients with either clinically confirmed endometriosis or other benign (non-cancerous) conditions.
The statistical modelling and subsequent independent study will prove if we have a viable, novel, non-invasive test for endometriosis, and we believe this program will garner significant interest, both commercially and in the clinic.
